Exhibitors Search
NodCure Inc.
Booth no.
H50
|
Exhibition
|
|KOREA LIFE SCIENCE |
|---|---|
|
Country
|
| Korea, South |
|
Address
|
|77 Yongbong-ro, Buk-gu, Jeonnam-Gwangju, Republic of Korea |
|
Tel
|
|+82-62-523-6966 |
|
Exhibits
|
| Anti-Canine PD-L1 Antibody for Companion Animal Cancer Immunotherapy |
|
Company Type
|
| Pharmaceutical / Drug Development Company , Biotech Venture / Startup |
Exhibitor Information
NodCure Inc. is a biotechnology venture founded by Professor Jong-Hwan Park of the College of Veterinary Medicine at Chonnam National University.
The company develops advanced biopharmaceuticals for companion animals and microbiome-based functional ingredients.
Its lead pipeline is an anti-canine PD-L1 antibody for the treatment of canine cancer. The program is currently preparing for cell culture and process development, while clinical proof-of-concept (PoC) studies are underway to evaluate its efficacy in combination with CHOP chemotherapy. NodCure is advancing the program toward domestic regulatory approval and global licensing-out (L/O).
In addition, NodCure is expanding its business portfolio through the development of microbiome-based functional ingredients and R&D services, leveraging its proprietary microbiome research capabilities.
The company develops advanced biopharmaceuticals for companion animals and microbiome-based functional ingredients.
Its lead pipeline is an anti-canine PD-L1 antibody for the treatment of canine cancer. The program is currently preparing for cell culture and process development, while clinical proof-of-concept (PoC) studies are underway to evaluate its efficacy in combination with CHOP chemotherapy. NodCure is advancing the program toward domestic regulatory approval and global licensing-out (L/O).
In addition, NodCure is expanding its business portfolio through the development of microbiome-based functional ingredients and R&D services, leveraging its proprietary microbiome research capabilities.
Exhibit Description
* Anti-Canine PD-L1 Antibody for Companion Animal Cancer Immunotherapy
1. Development of a canine-sequence IgG-based anti-PD-L1 antibody
2. Completed in vivo efficacy studies in NOG mouse models of lymphoma and osteosarcoma
3. Completion of production cell line development, RCB banking, and non-GLP toxicity study
4. Ongoing clinical efficacy evaluation in combination with the CHOP protocol
1. Development of a canine-sequence IgG-based anti-PD-L1 antibody
2. Completed in vivo efficacy studies in NOG mouse models of lymphoma and osteosarcoma
3. Completion of production cell line development, RCB banking, and non-GLP toxicity study
4. Ongoing clinical efficacy evaluation in combination with the CHOP protocol
Individual Exhibit/Technology Introduction (Detailed)
-
Product Name : Anti-Canine PD-L1 Antibody for Companion Animal Cancer Immunotherapy* Anti-Canine PD-L1 Antibody for Companion Animal Cancer Immunotherapy 1. Development of a canine-sequence IgG-based anti-PD-L1 antibody 2. Completed in vivo efficacy studies in NOG mouse models of lymphoma and osteosarcoma 3. Completion of production cell line development, RCB banking, and non-GLP toxicity study 4. Ongoing clinical efficacy evaluation in combination with the CHOP protocol 5. Target by 2027: Establishment of cell culture and manufacturing process development, scale-up production, and completion of a GLP single-dose toxicity study
KYUNGYON EXHIBITION CORP.
